Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £311.75m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

7 Jan 2008 10:50

Avacta Group plc

Strategic Alliance

Broader service offering augments market position

Avacta Group plc ("Avacta"), which provides novel detection and analysis technology for the pharmaceutical, defence & security and clinical diagnostics markets, announces an agreement with Agenda 1 Analytical Services Ltd ("Agenda 1").

Agenda 1 provides a wide range of analytical techniques and services from bespoke laboratories located close to Avacta in Bradford, UK. Agenda 1 provides a complementary service offering to Avacta by focusing on small molecule therapeutics, whereas Avacta's strength is in the provision of expert analysis to companies developing large molecule biopharmaceuticals. Consequently, the agreement provides an immediate synergy allowing Avacta to offer an enhanced analytical service to a much wider base of pharmaceutical companies along with access to expertise, resources and technology not available in-house.

The Directors of Avacta believe that this enhanced product offering will enable accelerated growth of the analytical services business because it affords Avacta the ability to offer a greater range of the services required by the pharmaceutical industry. There will be no consideration payable by Avacta for this sharing of services.

Professor Alastair Smith, Chief Executive Officer, Commented:

"Avacta Analytical Limited, Avacta's technical services subsidiary, has made very good progress in its provision of analytical services to the biopharmaceutical sector but we are aware that some potential clients require an even broader range of services than we have been able to offer to date. Today's agreement allows us to extend our services and cover a greater range of the pharmaceutical industry's requirements and my expectation is that this will lead to more rapid growth in the services business of the Group."

7 January 2008Enquiries:Avacta Group plc Tel: 0870 835 4367 Russell Hodgetts Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk WH Ireland Ltd (Nominated Adviser) Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7562 4700 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes.

A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

About Agenda 1

Agenda 1 grew from the analytical laboratories of Nektar Therapeutics (UK) Ltd - (a.k.a. Bradford Particle Design Ltd). The team was formed to utilise their experience as a development group supporting both new technologies and new pharmaceutical products working from early stage project initiation up to and including enabling the release of material for clinical trials.

Agenda 1's client base ranges from major pharmaceutical companies through to virtual companies, and emerging and growing Bio-Pharma businesses. Agenda 1 has developed a number of flexible approaches to help clients access their lab facilities. These include the option to place contract staff into the laboratories via a unique structure with Synergy Outsourcing, a company specialising in scientific personnel. Agenda 1 has also recently launched an innovative "Lab Time-Share" approach, which saw the company awarded the prestigious Royal Society of Chemistry "SME of the month" award for July 2007.

AVACTA GROUP PLC
Date   Source Headline
5th May 20157:01 amRNSIssue of Equity
28th Apr 20157:00 amRNSHalf Yearly Report
8th Apr 20157:00 amRNSNotice of Results
23rd Mar 20157:00 amRNSDrug discovery partnership
23rd Mar 20157:00 amRNSIssue of Equity
12th Feb 20157:00 amRNSSale of Optim Trade and Assets
9th Feb 20157:00 amRNSAffimer Development Contract with Protatonce
23rd Jan 20152:31 pmRNSResult of AGM
23rd Jan 20157:00 amRNSTrading Statement
16th Jan 20157:00 amRNSCommercial Partnership in the Agri-bio Market
6th Jan 20157:00 amRNSIssue of Equity
22nd Dec 20147:00 amRNSPosting of Annual Report & Accounts and AGM Notice
16th Oct 20147:00 amRNSFinal Results
30th Sep 20147:00 amRNSAffimer On-line Catalogue Launch
29th Sep 20147:00 amRNSInvestor Briefing
22nd Sep 20147:00 amRNSAppointment of a Senior Executive
4th Aug 20147:00 amRNSNew OPTIM Software and Hardware
1st Aug 20147:00 amRNSPre Close Trading Update
15th Jul 20147:00 amRNSMajor Japanese Distributor Signed
13th Jun 201411:04 amRNSHolding(s) in Company
2nd Jun 20141:04 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSAvacta Secures Funding Award
30th May 20144:37 pmRNSHolding(s) in Company
30th May 20142:52 pmRNSHolding(s) in Company
29th May 20144:21 pmRNSHolding(s) in Company
28th May 20147:00 amRNSAvacta Life Sciences Exhibits Affimers at PEGS
23rd May 201412:53 pmRNSResult of General Meeting
21st May 20145:36 pmRNSHolding(s) in Company
14th May 20147:00 amRNSIssue of Equity
9th May 20144:19 pmRNSDirector's dealing
9th May 20147:00 amRNSAvacta Announce Collaboration with UbiQ Bio BV
7th May 20147:00 amRNSConditional Placing
23rd Apr 20147:00 amRNSInterim Results
14th Apr 20147:00 amRNSAvacta Launch Pancreatitis Test for Dogs
20th Mar 20147:00 amRNSAffimers : Technical and Commercial Update
11th Mar 20147:00 amRNSNotice of Interim Results
24th Feb 20147:00 amRNSDirectors Dealings
5th Feb 20147:00 amRNSNew Board Appointment
4th Feb 20149:29 amRNSHolding(s) in Company
3rd Feb 20147:00 amRNSAvacta Initiates Collaboration with University
28th Jan 20147:00 amRNSAvacta Life Sciences Launches Affimers Web Site
24th Jan 20142:57 pmRNSResult of AGM
24th Jan 20147:00 amRNSAGM Statement
20th Jan 20147:00 amRNSIssue of Equity
13th Jan 20147:00 amRNSInvestor teach-in
23rd Dec 20132:59 pmRNSNotice of AGM and Report and Accounts
23rd Dec 20137:00 amRNSBoard Appointment
27th Nov 201310:01 amRNSNew Canine Lymphoma Blood Test Launched
1st Nov 20137:00 amRNSIssue of Equity
24th Oct 20137:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.